Ali Fatehi Hassanabad MD, MSc , Darrell D. Belke PhD , Paul M.K. Gordon PhD , Guoqi Teng MD, PhD , Jameson A. Dundas BSc , Anna N. Zarzycki BSc , Jeannine Turnbull BSc, MSc , Justin F. Deniset PhD , Paul W.M. Fedak MD, PhD
{"title":"冠状动脉疾病患者的心包液能通过 TGF-Beta 通路促进纤维化","authors":"Ali Fatehi Hassanabad MD, MSc , Darrell D. Belke PhD , Paul M.K. Gordon PhD , Guoqi Teng MD, PhD , Jameson A. Dundas BSc , Anna N. Zarzycki BSc , Jeannine Turnbull BSc, MSc , Justin F. Deniset PhD , Paul W.M. Fedak MD, PhD","doi":"10.1016/j.jacbts.2024.06.007","DOIUrl":null,"url":null,"abstract":"<div><div>Human pericardial fluid (PF) is a rich reservoir of biologically active markers. The acellular compartment of PF can drive cardiac fibroblast activity in vitro. This process is mediated through the transforming growth factor-β pathway. Of clinical importance, the PF of patients with coronary artery disease has an increased profibrotic capacity compared with the PF of patients without coronary artery disease.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"9 11","pages":"Pages 1329-1344"},"PeriodicalIF":8.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pericardial Fluid of Patients With Coronary Artery Disease Can Drive Fibrosis Via TGF-Beta Pathway\",\"authors\":\"Ali Fatehi Hassanabad MD, MSc , Darrell D. Belke PhD , Paul M.K. Gordon PhD , Guoqi Teng MD, PhD , Jameson A. Dundas BSc , Anna N. Zarzycki BSc , Jeannine Turnbull BSc, MSc , Justin F. Deniset PhD , Paul W.M. Fedak MD, PhD\",\"doi\":\"10.1016/j.jacbts.2024.06.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Human pericardial fluid (PF) is a rich reservoir of biologically active markers. The acellular compartment of PF can drive cardiac fibroblast activity in vitro. This process is mediated through the transforming growth factor-β pathway. Of clinical importance, the PF of patients with coronary artery disease has an increased profibrotic capacity compared with the PF of patients without coronary artery disease.</div></div>\",\"PeriodicalId\":14831,\"journal\":{\"name\":\"JACC: Basic to Translational Science\",\"volume\":\"9 11\",\"pages\":\"Pages 1329-1344\"},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC: Basic to Translational Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2452302X24002523\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X24002523","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Pericardial Fluid of Patients With Coronary Artery Disease Can Drive Fibrosis Via TGF-Beta Pathway
Human pericardial fluid (PF) is a rich reservoir of biologically active markers. The acellular compartment of PF can drive cardiac fibroblast activity in vitro. This process is mediated through the transforming growth factor-β pathway. Of clinical importance, the PF of patients with coronary artery disease has an increased profibrotic capacity compared with the PF of patients without coronary artery disease.
期刊介绍:
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.